Our portfolio

To date, CEPI has established multiple partnership agreements, reflecting a potential investment of over $270 million. Through these collaborations, we're supporting the development of a wide range of vaccine candidates.

We also have number of additional partnerships under negotiation. These partnership agreements represent the start of CEPI’s product development portfolio. See below current details of our vaccine portfolio.

PRODUCT DEVELOPERS
  • All
  • IDT Biologika
  • Inovio
  • International AIDS Vaccine Initiative
  • New Vaccine Dev
  • Oxford University & Janssen Vaccines
  • Profectus BioSciences and Emergent BioSolutions
  • Thermis Bioscience
DISEASE
  • All
  • DNA vaccine
  • Modified Vaccinia Ankara vector
  • Nipah virus vaccine
  • Replication-deficient simian adenoviral vaccine vector, ChAdOx1
  • rVSVΔG-LASV-GPC
VACCINE TYPE
  • All
  • Lassa virus vaccine
  • MERS vaccine
  • Nipah virus vaccine
PHASE
  • All
  • Phase 1
  • Preclinical
{{ mob.finishButton }}
Filter by product developers:
Filter by disease:
Filter by vaccine type:
Filter by phase:

{{ dev['funding_title'] }}

{{ dev['funding'] }}

{{ d['disease'] }}
{{ d['vaccine_type'] }}
{{ d['trial_title'] }}
{{ d['trial'] }}
{{ d['phase'] }}
?
?

{{ d['description'] }}

N/A
No result